PCOD, obesity, and metabolic syndrome are not three separate problems — they are three faces of the same underlying disorder: insulin resistance. Treat them in isolation and patients struggle for years on multiple medications without real improvement. Treat them as a single connected disease, and the results are often dramatic.
At Nirvana Clinic in Greater Noida, I see this pattern almost every day. A woman comes in for irregular periods or unexplained weight gain. A man comes in for high blood pressure or fatty liver. The lab reports look like different problems. But when we look at the whole metabolic picture — fasting insulin, HbA1c, lipid profile, liver function, hormones — the same root cause appears.
This page explains what PCOD, obesity, and metabolic syndrome really are, how they connect, and how we treat them using a combined approach of lifestyle medicine, modern pharmacotherapy (including GLP-1 agonists like Ozempic and Mounjaro where appropriate), and long-term monitoring.
You should read on if you have any of these: irregular or missed periods with weight gain, BMI ≥27 with a family history of diabetes, central obesity (waist >90 cm men / >80 cm women), fatty liver on ultrasound, fasting blood sugar between 100–125 mg/dL, or unexplained skin darkening around the neck/armpits.
What we do differently: we treat the underlying insulin resistance, not just the surface symptoms. That means proper diagnostic workup, evidence-based weight management (including supervised GLP-1 therapy where indicated), and long-term metabolic monitoring — not just metformin and a diet sheet.
These three diagnoses share a single physiological root: insulin resistance. When the body's cells stop responding properly to insulin, the pancreas produces more of it. Chronically high insulin levels then trigger a cascade:
This is why a patient with PCOD often has a fatty liver, why a patient with metabolic syndrome often has prediabetes, and why weight loss in any one of these conditions dramatically improves all the others. You don't have three problems — you have one problem with three names.
Most patients walk in with one or two symptoms but actually have several when we look properly. Here are the warning signs that bring patients to me most often:
The clinical criteria are straightforward — you need three or more of the following:
| Criterion | Threshold |
|---|---|
| Waist circumference | >90 cm (men) or >80 cm (women) — South Asian cutoffs |
| Fasting blood glucose | ≥100 mg/dL (or on diabetes treatment) |
| Blood pressure | ≥130/85 mmHg (or on BP treatment) |
| Triglycerides | ≥150 mg/dL |
| HDL cholesterol | <40 mg/dL (men) or <50 mg/dL (women) |
If you meet three or more of these, your cardiovascular risk is 2–3 times higher than the general population, and your diabetes risk is 5 times higher. The earlier we act, the more reversible this is.
Treating PCOD, obesity, and metabolic syndrome in isolation usually fails. Treating them as a single insulin-resistance disorder works. Here is the protocol I follow:
Beyond fasting sugar and lipids, we test: fasting insulin (calculate HOMA-IR), HbA1c, complete thyroid profile, vitamin D and B12, hormonal panel for women (LH, FSH, AMH, free testosterone, SHBG), liver function with ultrasound or FibroScan if indicated, and apo-B for advanced cardiovascular risk. This is what reveals whether you have insulin resistance specifically, even if your sugars are still "normal."
"Eat less, exercise more" doesn't work. We give an Indian-specific protein-first eating plan (typically 1.2–1.6 g protein per kg body weight), structured resistance training (not just walking — muscle is metabolically protective), sleep optimisation (poor sleep alone causes insulin resistance), and stress modulation. The lifestyle plan is matched to your specific lab profile.
Metformin remains first-line for insulin resistance in PCOD and prediabetes. For appropriate patients with BMI ≥27 and metabolic syndrome, we now offer supervised GLP-1 therapy — semaglutide (Ozempic, Wegovy, generics) or tirzepatide (Mounjaro, Yurpeak). These medications have transformed obesity and metabolic syndrome care; see my detailed guide on GLP-1 therapy for PCOS in India for full information.
If you have fatty liver, we treat it actively (see our fatty liver programme). If you have hypertension, we use metabolic-friendly antihypertensives. If you have thyroid issues, we optimise thyroid status because untreated hypothyroidism worsens insulin resistance.
Metabolic disease is a chronic condition, not a one-visit fix. We schedule structured follow-ups at 6 weeks, 3 months, 6 months, and then annually. Labs are repeated to track improvement. Medications are adjusted, escalated, or withdrawn as your metabolism corrects. The goal is sustained remission, not lifelong dependency on pills.
Already considering GLP-1 medications for weight loss? My detailed comparison of Mounjaro vs Wegovy in India covers cost, effectiveness, and which is right for your specific situation.
Read GuidePCOD (polycystic ovarian disease) is the most common hormonal disorder in Indian women of reproductive age. Roughly 1 in 5 Indian women has it, but most cases are diagnosed years late because the symptoms — irregular periods, weight gain, acne — are dismissed as "stress" or "hormonal imbalance" without proper workup.
The full PCOD picture includes:
Treatment for PCOD needs to address all four domains. We work alongside Dr. Debolina Chowdhury for the mental health aspect when needed — integrated diabetes-psychiatry care is one of Nirvana Clinic's core offerings.
For decades, obesity was treated as a willpower problem. The science has moved on. Obesity is now understood as a chronic metabolic disease driven by hormonal dysregulation — appetite hormones, insulin, leptin resistance — that lifestyle alone often cannot fully correct in patients with established obesity.
For patients with BMI ≥27 plus comorbidities, or BMI ≥30, we discuss:
Want to know if diabetes is reversible for you? Try our free diabetes remission calculator — it estimates your likelihood of remission based on age, weight, diabetes duration, and HbA1c.
Open CalculatorI am an MRCP UK-trained physician and diabetologist. That training matters here because metabolic disease sits at the intersection of multiple specialties — endocrinology, internal medicine, hepatology, cardiology — and most patients get bounced between specialists who each treat one piece in isolation.
At Nirvana Clinic, we offer:
The terms are often used interchangeably in India, but technically PCOD (polycystic ovarian disease) refers to ultrasound findings of multiple follicles on the ovary, while PCOS (polycystic ovary syndrome) refers to the full clinical syndrome of irregular periods, raised androgens, and ovarian cysts. PCOS is the more accurate medical term, but both describe the same underlying insulin resistance disorder. At Nirvana Clinic, we treat the metabolic root cause regardless of the label.
PCOD is not technically "curable" because the genetic predisposition stays, but the symptoms and metabolic consequences are highly reversible with proper treatment. With 10–15% body weight loss combined with appropriate medication, the majority of women regain regular periods, see acne and hair issues improve, restore fertility, and prevent progression to diabetes. The key is treating it as a chronic metabolic disease — not waiting for it to "go away."
For early or mild cases — BMI under 27, regular periods returning with weight loss, no prediabetes — lifestyle alone often works. For established cases with significant insulin resistance, prediabetes, or BMI ≥27 with metabolic syndrome, medication added to lifestyle achieves results that lifestyle alone usually cannot in a reasonable timeframe. The medication isn't replacing diet and exercise; it makes them work better. We discuss this honestly based on your specific clinical picture.
Metformin is an inexpensive, well-tolerated insulin sensitiser that helps many — but not all — PCOD patients. It is most effective for women with documented insulin resistance, raised fasting insulin or HbA1c, or BMI ≥25. It is not a one-size-fits-all prescription. Side effects (GI upset) usually settle within 2 weeks if titrated properly. We start with the extended-release formulation at the lowest effective dose and titrate up.
GLP-1 receptor agonists (semaglutide, tirzepatide) are clinically appropriate for women with PCOD who also meet obesity criteria (BMI ≥27 with comorbidities, or BMI ≥30). They are highly effective for weight loss, insulin resistance, and the metabolic features of PCOD. They are not appropriate for slim PCOD patients, women actively trying to conceive (must stop 2 months before conception), or pregnancy. Safety, contraindications, and cost should be discussed thoroughly with a physician before starting. See my detailed GLP-1 for PCOS guide.
The first consultation is 45 minutes minimum. We take a detailed history (symptoms, menstrual pattern, family history, lifestyle, prior treatments), measure weight, height, waist circumference, blood pressure. We then order appropriate investigations — usually a metabolic panel including fasting insulin (HOMA-IR), HbA1c, complete thyroid, hormonal profile, lipid profile, liver function with ultrasound, and vitamin D. You return with results in 1–2 weeks for a treatment plan discussion. Cost of consultation is explained upfront on booking.
Yes. Although PCOD is specific to women, metabolic syndrome and obesity affect both sexes equally. Men with central obesity, high BP, fatty liver, prediabetes, or low testosterone secondary to obesity are treated under the same protocol. Roughly 40% of metabolic patients in my practice are men.
Realistic milestones: weight loss of 1–2 kg per week in the first 2 months on appropriate treatment. HbA1c improvement of 0.5–1% in 3 months. Periods often regularise within 3–6 months of starting treatment for PCOD. Fatty liver improves on ultrasound by 6 months. Full metabolic recovery — normalised fasting insulin, off-medication remission — typically takes 12–18 months of consistent treatment in motivated patients.
Yes. After the first in-person consultation (which we recommend for proper examination and rapport-building), follow-ups can be done online. We offer secure online consultations for patients across India and internationally — particularly useful for NRI patients in UAE, USA, UK, and Australia/Singapore who want continuity of metabolic care with an MRCP UK physician.
PCOD, obesity, and metabolic syndrome are highly treatable — but only when treated as a connected disease, not as separate complaints. Book a 45-minute consultation with Dr. Manuj Sondhi at Nirvana Clinic, Greater Noida, or via online consultation for patients across Delhi NCR and abroad.